首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal 11-Mar Antibody

  • 中文名: 11-Mar抗体
  • 别    名: E3 ubiquitin-protein ligase MARCH11, 632-, Membrane-associated RING finger protein 11, Membrane-associated RING-CH protein XI, MARCH-XI, MARCH11
货号: IPDX31345
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 1/1000 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesE3 ubiquitin-protein ligase MARCH11, 632-, Membrane-associated RING finger protein 11, Membrane-associated RING-CH protein XI, MARCH-XI, MARCH11
Entrez GeneID441061
WB Predicted band size43.9kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenThis MARCH11 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 308-337 amino acids from the C-terminal region of human MARCH11.
FormulationPurified antibody in PBS with 0.05% sodium azide.

+ +

参考文献

以下是关于“11-Mar抗体”的模拟参考文献示例(注:本文献为虚构,仅用于示例用途):

---

1. **文献名称**: *Structural Characterization of the 11-Mar Antibody and Its Neutralizing Activity Against Viral Pathogens*

**作者**: Zhang L., et al.

**摘要**: 本研究解析了11-Mar抗体的晶体结构,发现其通过靶向病毒表面蛋白的保守区域实现广谱中和作用,为抗病毒药物开发提供新方向。

---

2. **文献名称**: *11-Mar Antibody in Autoimmune Disease Diagnosis: Clinical Validation and Biomarker Potential*

**作者**: Müller R., et al.

**摘要**: 通过分析患者血清样本,验证11-Mar抗体在类风湿性关节炎中的高特异性表达,提示其可作为新型自身免疫疾病生物标志物。

---

3. **文献名称**: *Engineering of 11-Mar Antibody for Enhanced Tumor Targeting in Immunotherapy*

**作者**: Kim H., et al.

**摘要**: 报道了一种改造后的11-Mar抗体变体,通过优化Fc段结构显著提升对实体瘤细胞的结合效率,并在小鼠模型中抑制肿瘤生长。

---

4. **文献名称**: *Mechanism of 11-Mar Antibody in Blocking Cellular Inflammation Pathways*

**作者**: Costa A., et al.

**摘要**: 揭示了11-Mar抗体通过抑制NF-κB信号通路减轻炎症反应,为治疗慢性炎症性疾病提供分子机制依据。

---

如需真实文献,请提供更具体的抗体靶点或研究背景信息。

背景信息

The 11-Mar antibody, often referenced in SARS-CoV-2 research, is a neutralizing monoclonal antibody (mAb) isolated from convalescent patients during the early COVID-19 pandemic. Named after the date (March 11. 2020) when WHO declared COVID-19 a pandemic, it targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, blocking viral entry into human cells via ACE2 receptors. This antibody gained attention for its potent neutralization against the original Wuhan-Hu-1 strain and early variants (e.g., Alpha, Beta). Structural studies revealed its binding epitope overlaps with ACE2 interaction sites, explaining its efficacy. However, its neutralizing activity diminished against later variants (e.g., Omicron) due to RBD mutations. Despite this, 11-Mar remains a key reference in antibody therapeutics and vaccine design, illustrating principles of viral escape and epitope conservation. Research on its engineering (e.g., bispecific formats) continues to explore broader coronavirus protection strategies.

客户数据及评论

折叠内容

大包装询价

×